Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 16;13:3463. doi: 10.1038/s41467-022-31196-5

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 2 — a Vaccination significantly and durably increased the size of SHIV-specific cellular immune IFN-γ responses over time in comparisons with pre-vaccination responses (“Pre”, week 24). Mean ± standard error is shown. b Vaccination significantly increased the breadth of SHIV-specific cellular immune IFN-γ responses in comparison to sham treatment. Means and standard errors are shown. c Vaccination significantly increased antibody binding to clade C and mosaic (mosaic 1) HIV-1 Env with median indicated. Two-sided Mann–Whitney tests were used to determine significance in non-paired analyses (a, c), and two-sided Wilcoxon matched-pairs sign rank tests were used in paired analyses (b). Sham = sham treatment; ‘bNAb’ or ‘PGT121 + VES’ = PGT121 + vesatolimod treatment; ‘Vax’ or ‘Ad26/MVA + VES’ = Ad26/MVA + vesatolimod treatment; and ‘bNAb + Vax’ or ‘Ad26/MVA + PGT121 + VES’ = Ad26/MVA, PGT121, + vesatolimod treatment. *p < 0.05 (in a, from left to right, p = 0.184 and 0.0339 for Sham; in c, p = 0.0465 in Clade C and 0.0489 in Mosaic M), **p < 0.01 (in a, from left to right, p = 0.0072 and 0.0016 for Sham, 0.0024 and 0.0068 for bNAb, and 0.002 for bNAb + Vax; in c, p = 0.0013), ***p < 0.001 (in a, from left to right, p = 0.005 for Sham, 0.0005 for all Vax, and 0.001 for bNAb + Vax from weeks 28 to 50; in c, p = 0.0008), ****p < 0.0001.